AERIE PHARMACEUTICALS INC (AERI) Stock Price, Forecast & Analysis
USA - NASDAQ:AERI - US00771V1089 - Common Stock
AERI Key Statistics, Chart & Performance
The current stock price of AERI is 15.25 USD. In the past month the price increased by 0.26%. In the past year, price increased by 51.89%.
AERI Latest News, Press Relases and Analysis
AERI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.28 | 963.29B | ||
| JNJ | JOHNSON & JOHNSON | 18.73 | 468.16B | ||
| MRK | MERCK & CO. INC. | 10.38 | 228.42B | ||
| PFE | PFIZER INC | 8.08 | 147.09B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.48 | 99.90B | ||
| ZTS | ZOETIS INC | 19.12 | 53.74B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.63 | 23.09B | ||
| VTRS | VIATRIS INC | 4.73 | 12.84B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.97 | 10.95B | ||
| CORT | CORCEPT THERAPEUTICS INC | 89.08 | 8.26B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.03B | ||
| LGND | LIGAND PHARMACEUTICALS | 28.2 | 4.03B |
Related stock screener links
About AERI
Company Profile
Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. The company is headquartered in Durham, North Carolina and currently employs 376 full-time employees. The company went IPO on 2013-10-25. The firm is focused on the discovery, development and commercialization of ophthalmic therapies for the treatment of patients with eye diseases and conditions, including open-angle glaucoma, dry eye, diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). The firm's commercial products include Rhopressa and Rocklatan. Rhopressa is a once-daily eye drop designed to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Rhopressa increases the outflow of aqueous humor through the trabecular meshwork (TM), which accounts for approximately 80% of fluid drainage from the healthy eye and is the diseased tissue responsible for elevated IOP in glaucoma. Rocklatan is a once-daily fixed-dose combination of Rhopressa and latanoprost, a drug for the treatment of patients with open-angle glaucoma or ocular hypertension.
Company Info
AERIE PHARMACEUTICALS INC
4301 Emperor Boulevard, Suite 400
Durham NORTH CAROLINA 27703 US
CEO: Vicente Anido Jr
Employees: 376
Phone: 19192375300.0
AERIE PHARMACEUTICALS INC / AERI FAQ
What does AERI do?
Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. The company is headquartered in Durham, North Carolina and currently employs 376 full-time employees. The company went IPO on 2013-10-25. The firm is focused on the discovery, development and commercialization of ophthalmic therapies for the treatment of patients with eye diseases and conditions, including open-angle glaucoma, dry eye, diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). The firm's commercial products include Rhopressa and Rocklatan. Rhopressa is a once-daily eye drop designed to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Rhopressa increases the outflow of aqueous humor through the trabecular meshwork (TM), which accounts for approximately 80% of fluid drainage from the healthy eye and is the diseased tissue responsible for elevated IOP in glaucoma. Rocklatan is a once-daily fixed-dose combination of Rhopressa and latanoprost, a drug for the treatment of patients with open-angle glaucoma or ocular hypertension.
Can you provide the latest stock price for AERIE PHARMACEUTICALS INC?
The current stock price of AERI is 15.25 USD. The price increased by 0.07% in the last trading session.
What is the dividend status of AERIE PHARMACEUTICALS INC?
AERI does not pay a dividend.
How is the ChartMill rating for AERIE PHARMACEUTICALS INC?
AERI has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for AERI stock?
14 analysts have analysed AERI and the average price target is 15.63 USD. This implies a price increase of 2.48% is expected in the next year compared to the current price of 15.25.
Can you provide the number of employees for AERIE PHARMACEUTICALS INC?
AERIE PHARMACEUTICALS INC (AERI) currently has 376 employees.
AERI Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to AERI. When comparing the yearly performance of all stocks, AERI is one of the better performing stocks in the market, outperforming 98.08% of all stocks.
AERI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AERI. While AERI is still in line with the averages on profitability rating, there are concerns on its financial health.
AERI Financial Highlights
Over the last trailing twelve months AERI reported a non-GAAP Earnings per Share(EPS) of -0.16. The EPS increased by 94.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -17.09% | ||
| ROA | -9.73% | ||
| ROE | N/A | ||
| Debt/Equity | -1.91 |
AERI Forecast & Estimates
14 analysts have analysed AERI and the average price target is 15.63 USD. This implies a price increase of 2.48% is expected in the next year compared to the current price of 15.25.
For the next year, analysts expect an EPS growth of -85.62% and a revenue growth 23.8% for AERI